top of page

Search Results

Results found for "neuroma model"

  • Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem

    Terry Hebert explains why studying GPCRs in HEK293 cells misses critical biology — and how iPSC-derived models cell type, and is now deploying them in iPSC-derived cardiomyocytes and patient-specific stem cell models failure of a biased agonist exposed the cost of oversimplifying that signaling landscape. iPSC-Derived Models biosensors revealing cell-type-dependent outputs 10:54 Building the toolkit — biosensors, iPSC-derived models

  • Gáspár Pándy-Szekeres | Dr. GPCR Ecosystem

    My initial focus was on creating an automated chimeric homology modeling pipeline for GPCRs and since

  • Dr. Lukas Grätz | Dr. GPCR Ecosystem

    My initial focus was on creating an automated chimeric homology modeling pipeline for GPCRs and since

  • Dr. Kenneth A. Jacobson | Dr. GPCR Ecosystem

    He adapts interdisciplinary approaches (synthesis, modeling, pharmacology) to study G protein-coupled

  • Dr. Graham Ladds | Dr. GPCR Ecosystem

    His research group uses a combination of pharmacological investigations and mathematical modeling to

  • Dr. Benjamin Myers | Dr. GPCR Ecosystem

    transmembrane receptors, combining biochemical and structural approaches with cell biology and in vivo models

  • GPCR Webinars | Dr. GPCR Ecosystem

    David Hodson Topics Covered: LUXendin probes for GLP-1R labeling across imaging modalities daLUXendin Each session explores mechanistic models, translational challenges, and real-world therapeutic implications GPCR pharmacology, signaling, structural biology, allosteric modulation, biased agonism, assay design

  • Dr. Marta Filizola | Dr. GPCR Ecosystem

    computational structural biology tools and rational drug design approaches, ranging from molecular modeling

  • Dr. Nicola J. Smith | Dr. GPCR Ecosystem

    the understanding of how an orphan GPCR exerts its effects both in vitro (cell culture and ex vivo models

  • Developing new tools to uncover GPCR signaling patterns with Remi Janicot | Dr. GPCR Ecosystem

    Overall, the lab works on diverse models and diseases, and has developed a wide array of tools to dissect

  • Annette Gilchrist: Native Cell Systems, Biased Agonism, and the Pharmacogenomics Gap | Dr. GPCR Ecosystem

    much as a confirmation - if you look in the right system, receptors show you things overexpression models SCIENTIFIC THEMES OF THE CONVERSATION The native cell argument - why overexpression models produce systematically you screen in determines the biology you can find Running a GPCR screen in a HEK cell overexpression model proteins a receptor actually encounters in disease tissue - effectors like Go or Gz that are critical in neuronal direct product of that discipline - a result that would have been invisible in a standard overexpression model

  • GPCR Retreat | Dr. GPCR Ecosystem

    University in Australia, one of the pioneers in the medicinal chemistry, computational and mathematical modelling scientists working in the arenas of structure and signaling, neuroscience, cancer, translational and model

  • Dr. Tobi Langenhan | Dr. GPCR Ecosystem

    I work with invertebrate animal models (mainly D. melanogaster) and in vitro techniques to pick apart adhesion GPCRs, and extends to the development of novel screening approaches to identify pharmacological modulators

  • Dr. Sai Prasad Pydi | Dr. GPCR Ecosystem

    His laboratory uses knock-out and transgenic mouse models, along with different cell culture systems,

  • Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem

    Her work spans GPCR structural biology, membrane protein stabilization, allosteric modulation, and the extra-helical pockets on the glucagon receptor, intracellular sites for C5a antagonists, allosteric modulators only survives translation if the coupling profile in the relevant human cells matches the cell-line model Marshall's caution is hard-won: many animal-model-validated GPCR drugs have failed in the clinic precisely wave of GPCR drug design 18:47 Which GPCR families pharma is chasing now — and why 21:23 Why animal model

  • Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem

    steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models Slosky characterized a new class of β-arrestin biased allosteric modulators (BAMs) for the neurotensin Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects

  • Dr. Nariman Balenga | Dr. GPCR Ecosystem

    the role of RGS4 and RGS5 in airway hyperresponsiveness and lung fibrosis in acute and chronic mouse models A fungal serine protease allergen with GPCR-modulating features was discovered as a new biomarker and

  • Dr. Kathleen Caron | Dr. GPCR Ecosystem

    steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models

  • Dr. GPCR Board | Dr. GPCR Ecosystem

    critical expertise, and rigorous approaches to examine PAR1 function using human cultured cells and mouse models San Diego Supercomputer Center, and provided consultation for genetic sequence analysis, molecular modeling

  • Anything BUT GPCRs with Dr. Mikel Garcia-Marcos | Dr. GPCR Ecosystem

    (biochemistry, cell biology, genetics) and experimental systems (purified proteins, cultured cells, model

  • GPCR Weekly News | Dr. GPCR Ecosystem

    Premium members get the complete intelligence. iPSC-Derived GPCR Models — Terry Hébert Live April 16

  • Dr. Jean Martin Beaulieu | Dr. GPCR Ecosystem

    The Beaulieu group is presently investigating how cell surface express proteins can act as allosteric modulators Translational validation is important to validate findings obtained from experimental models research

  • Dr. JoAnn Trejo | Dr. GPCR Ecosystem

    critical expertise, and rigorous approaches to examine PAR1 function using human cultured cells and mouse models

  • Dr. Simone Prömel & Dr. Ines Liebscher | Dr. GPCR Ecosystem

    There she focused on the different modes of action of Adhesion GPCRs and found that they do not only different signals on a molecular level and how these are translated into physiological functions in various model

  • Dr. Lauren M. Slosky | Dr. GPCR Ecosystem

    Slosky characterized a new class of β-arrestin biased allosteric modulators (BAMs) for the neurotensin Critically, these ligands reduce addiction-associated behaviors in animal models without the side effects

  • Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology , molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease

  • Dr. Arthur Christopoulos | Dr. GPCR Ecosystem

    His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology , molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease

  • Paul Insel: Unbiased Discovery and the GPCRs We've Been Missing | Dr. GPCR Ecosystem

    combines bioinformatic analysis of GPCR expression across human cancers with wet-lab validation in animal models studied receptor function in human physiology, receptor molecular pharmacology in cells, and animal models

  • Sam Hoare: Receptor Residence Time and GPCR Data Analysis | Dr. GPCR Ecosystem

    Sam Hoare brings a data analyst's perspective to GPCR pharmacology — one trained in allosteric modulation After a PhD on allosteric modulation of dopamine receptors in Philip Strange's UK lab and a postdoc at biotech and pharmaceutical clients on GPCR data analysis, receptor binding kinetics, and pharmacological modeling The underlying pharmacological theory, from operational models of agonism to allosteric binding equations Samuel Hoare Sam completed his Ph.D. in biochemistry, studying allosteric modulation of dopamine receptors

  • From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem

    interested in translational innovation Biotech investors and strategic leaders seeking new drug development models

bottom of page